Dose-finding Study for SAR442168 in Relapsing Multiple Sclerosis

• Status: Completed
• Trial end date: 2020-01-02
• Target enrollment: 0
• Participant gender: All

Summary

Primary Objective:

To determine the dose-response relationship for SAR442168 to reduce the number of new active brain lesions.

Secondary Objectives:

• To evaluate efficacy of SAR442168 on disease activity as assessed by imaging measures.

• To evaluate the safety and tolerability of SAR442168.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanofi

Criteria

Inclusion criteria:

• Participant must be 18 to 55 years of age, inclusive, at the time of signing the informed consent.

• Participant was diagnosed with relapsing multiple sclerosis (RMS) according to the 2017 revision of the McDonald diagnostic criteria.

• Participant must had at least 1 documented relapse within the previous year, OR greater than or equal to (>=) 2 documented relapses within the previous 2 years, OR >=1 active Gadolinium (Gd) enhancing brain lesion on an MRI scan in the past 6 months and prior to screening.

• A female participant must had used a double contraception method including a highly effective method of birth control from inclusion and up to 2 months after the last study dose, except if she had undergone sterilization at least 3 months earlier or was postmenopausal. Menopause was defined as being amenorrheic for >=12 months with serum follicle-stimulating hormone (FSH) level greater than (>) 30 International Units per liters.

• Male participants, whose partners were of childbearing potential (including breastfeeding women), must had accepted to use, during sexual intercourse, a double contraceptive method according to the following algorithm: (condom) plus (intrauterine device or hormonal contraceptive) from inclusion up to 3 months after the last dose.

• Male participants whose partners were pregnant must had used, during sexual intercourse, a condom from inclusion up to 3 months after the last dose.

• Male participants had agreed not to donate sperm from the inclusion up to 3 months after the last dose.

• Participant had given written informed consent prior to undertaking any study-related procedure.

Exclusion criteria:

• The participant had been diagnosed with primary progressive multiple sclerosis according to the 2017 revision of the McDonald diagnostic criteria or with non relapsing secondary progressive multiple sclerosis.

• Requirement for concomitant treatment that could bias the primary evaluation.

• Contraindication for MRI.

• Contraindications to use MRI Gd contrast-enhancing preparations.

• History of infection with the human immunodeficiency virus (HIV).

• History of active or latent tuberculosis.

• Any other active infections that would adversely affect participation or investigational medicinal product administration in this study, as judged by the Investigator.

• Presence of any screening laboratory or electrocardiogram values outside normal limits that were considered in the Investigator's judgment to be clinically significant.

• Presence of liver injury.

• At screening, the participant was positive for hepatitis B surface antigen and/or hepatitis B core antibody and/or was positive for hepatitis C antibody.

• Bleeding disorder or known platelet dysfunction at any time prior to screening visit.

• Participant had received any live (attenuated) vaccine (including but not limited to varicella zoster, oral polio, and nasal influenza) within 2 months before first treatment visit.

• Participant was receiving strong inducers or inhibitors of cytochrome P450 3A (CYP3A) or CYP2C8 hepatic enzymes.

• Participant was receiving anticoagulant/antiplatelet therapies.

• Participant had taken other investigational drugs within 3 months or 5 half lives, whichever was longer, before screening visit.

• Participant had an Expanded Disability Status Scale score >5.5 at first screening visit.

• Participant had a relapse in the 30 days prior to randomization.

• Participant was pregnant or a breastfeeding woman.

• History or presence of significant other concomitant illness.

• The participant had received medications/treatments for multiple sclerosis within a specified time frame.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.